Sign In
Buy KYMR
$110.40
-8.95 (-7.50%)
At Close: Jul 13, 2026
Kymera's CEO Sold $6 Million in Stock After a 170% Run
04:37pm, Sunday, 12'th Jul 2026
According to a Form 4, proceeds of approximately $6.0 million were realized from the exercise and immediate sale of 50,000 shares at $119.00 per share on July 7, 2026. The transaction reduced the insi
Dr. Laws, former immunology leader at Sanofi, will oversee global development of Kymera's KT-621 program KT-621 parallel Phase 2b trials advancing in AD and asthma, with data expected by year-end 2026
Kymera Therapeutics: Why It May Be Time To Jump On The Bandwagon (Upgrade)
10:44am, Friday, 03'rd Jul 2026
Kymera Therapeutics (KYMR) is upgraded to Buy, driven by strong pipeline progress and a robust $1.5bn cash position. KT-621, an oral STAT6 degrader for atopic dermatitis, has accelerated Phase 2b time
Kymera: Building Toward A Defining 2H26 Moment
05:24am, Friday, 03'rd Jul 2026
Kymera Therapeutics is rated Buy ahead of the 2H26 KT-621 Phase 2b readout, seen as a key inflection point. KT-621, a first-in-class oral STAT6 degrader, targets large, expanding markets in atopic der
KYMR Stock Soars 51% YTD on Progress of Atopic Dermatitis Drug
02:11pm, Wednesday, 01'st Jul 2026
KYMR surges 51% year to date as KT-621 advances in atopic dermatitis and asthma, with pivotal data timelines accelerating and pipeline momentum building.
Why Kymera Therapeutics Stock Popped This Week
06:45pm, Friday, 26'th Jun 2026
It completed the enrollment phase of a Phase 2b study of its leading drug candidate. This medication will be trialed to gauge its efficacy in treating severe atopic dermatitis.
Kymera Jumps 17% on Early Enrollment Completion in Skin Disease Study
11:30am, Friday, 26'th Jun 2026
KYMR stock soars 17% as investor optimism was lifted following early enrollment completion in mid-stage AD study, moving KT-621 top-line data to year-end 2026.
Strength Seen in Kymera Therapeutics (KYMR): Can Its 16.6% Jump Turn into More Strength?
06:21am, Friday, 26'th Jun 2026
Kymera Therapeutics (KYMR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near t
Kymera Therapeutics Stock Climbs On Accelerated Timeline For Lead Atopic Dermatitis Program
01:19pm, Thursday, 25'th Jun 2026
Kymera Therapeutics Inc. (NASDAQ:KYMR) shares are trading higher by more than 21% on Thursday as the company has completed enrollment in its BROADEN2 Phase 2b trial for KT-621, a treatment for moderat
Biotech ETF Index Surges 10% After Rebalance
11:31am, Thursday, 25'th Jun 2026
After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs ETF (SBIO) gained over 10% in just six trading days beginning June 18. Key Takeaways: SBIO's underly
BROADEN2 enrollment completed nearly six months ahead of anticipated timelines KT-621 Phase 3 trials in AD planned to initiate by mid-2027 KT-621 BREADTH Phase 2b asthma trial ongoing, with data expec
Kymera Therapeutics Appoints Felix J. Baker, Ph.D.
04:01pm, Wednesday, 24'th Jun 2026
Bruce Booth, DPhil, Co-Founder and Chairman, to remain an Independent Director WATERTOWN, Mass., June 24, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmac
Kymera Therapeutics (KYMR) Soars 10.0%: Is Further Upside Left in the Stock?
11:25am, Tuesday, 23'rd Jun 2026
Kymera Therapeutics (KYMR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price in
Oral presentation at JDA features new data from the KT-621 Phase 1 study in healthy Japanese adults, with safety and PK/PD results consistent with previously reported KT-621 clinical studies
Healthcare ETFs: From Broad Exposure to Big Breakthroughs
07:14am, Thursday, 11'th Jun 2026
With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sect
